Modern Healthcare News
 
RSS feed

Gilead Sciences news and information

News
8% of patients stop taking Sovaldi, CVS study finds
By Jaimy Lee | September 17, 2014 | Basic Web Basic Web Subscription Details
About 8% of the patients who started taking Sovaldi to treat hepatitis C discontinued their treatment regimen prior to its conclusion, according to an analysis released Wednesday by CVS Health. The findings raise questions about how effective the costly drug will be in a larger patient population...
FULL STORY »
 

Information
Maker of hepatitis C drug strikes deal on generics for poor countries
By New York Times | September 15, 2014
Gilead Sciences, the maker of one of the costliest drugs in the world, announced on Monday that it had struck agreements with seven Indian generic-drug makers to sell lower-cost versions of the medicine—a $1,000-a-pill hepatitis C treatment—in poorer countries.
FULL STORY »
 

Magazine
IT entrepreneurs rush into healthcare, but will human touch be missing?
By Darius Tahir | September 06, 2014 | Print Magazine Print Magazine Subscription Details
The vision of providing better, faster, cheaper and more consumer-friendly healthcare is shared by many digital health and telehealth startups. Still, shifting healthcare services to the digital realm involves new challenges in ensuring quality and appropriate utilization.
FULL STORY »
 

News
Generic drugs, low enrollment dampened Medicare Part D spending: CBO
By Bob Herman | July 30, 2014 | Basic Web Basic Web Subscription Details
The cost of Medicare Part D, the federal prescription drug program, has been far lower than originally predicted, new data from the Congressional Budget Office show. A massive slowdown in drug spending growth and low participation in the program have played the biggest roles.
FULL STORY »
 

Vital Signs
Sovaldi likely to cost Medicare billions
By Virgil Dickson | July 29, 2014
The rising cost of hepatitis C drugs like Sovaldi and Olysio will increase Medicare Part D spending by $2.9 billion to $5.8 billion next year and could drive up premiums as much as 8.6%, according to a new report by the actuarial firm Milliman.
FULL STORY »
 


Advertisement | View Media Kit

Magazine
Sovaldi fuels earnings jump for Gilead
By Virgil Dickson | July 26, 2014 | Print Magazine Print Magazine Subscription Details
Gilead Sciences' second-quarter earnings blew through year-ago levels, thanks in part to its blockbuster, controversial hepatitis C drug Sovaldi.
FULL STORY »
 

News
Gilead reports massive Q2 earnings jump thanks to Sovaldi
By Virgil Dickson | July 23, 2014 | Basic Web Basic Web Subscription Details
Gilead Science's second-quarter earnings blew through year-ago levels, thanks in part to its blockbuster, and controversial, hepatitis C drug Sovaldi.
FULL STORY »
 

Information
HIV pills show more promise to prevent infection
By Associated Press | July 22, 2014
There is more good news about HIV treatment pills used to prevent infection in people at high risk of getting the AIDS virus: Follow-up from a landmark study that proved the drug works now shows that it does not encourage risky sex and is effective even if people skip some doses.
FULL STORY »
 

News
Senators want answers about Sovaldi's price tag
By Paul Demko | July 11, 2014 | Basic Web Basic Web Subscription Details
Sens. Ron Wyden (D-Ore.), chairman of the Finance Committee, and Chuck Grassley (R-Iowa), the ranking minority member of the Judiciary Committee, sent a letter Friday to the chairman and CEO of Sovaldi manufacturer Gilead Sciences with questions about how the drug's price was determined.
FULL STORY »
 

News
Reform makes cash tight for providers, but not pharma and payers
By Bob Herman | June 20, 2014 | Basic Web Basic Web Subscription Details
Hospitals and other providers face more financial challenges, and perhaps more near-term credit downgrades, than health insurers and pharmaceutical companies as healthcare reform unfolds, according to a new report from Standard & Poor's.
FULL STORY »
 

Search ModernHealthcare.com:


 

Switch to the new Modern Healthcare Daily News app

For the best experience of ModernHealthcare.com on your iPad, switch to the new Modern Healthcare app — it's optimized for your device but there is no need to download.